Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Joseph Klein | M | 62 | 19 years | |
Suneet Varma | M | 55 | 23 years | |
Matt Buck | M | - | 19 years | |
Mike McDermott | M | 58 | 21 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jeffrey Kindler | M | 68 | 8 years | |
George A. Lorch | M | 82 | 15 years | |
Jeffrey Stein | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
John Schmid | M | 61 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 9 years |
Vivid Sehgal | M | 56 | 8 years | |
Everett Cunningham | M | 57 | 9 years | |
John Thompson | M | 57 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 7 years |
Michael Morneau | M | 58 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
Sharon Real | M | 60 |
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | 12 years |
George Milne | M | 80 | 32 years | |
Olivier Brandicourt | M | 68 | 13 years | |
Theodore Schroeder | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 4 years |
Risa Stack | M | 55 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
Brendan M. O'Leary | M | 52 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 3 years |
Donald D. Tartre | M | 64 |
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | 4 years |
Dawn Hudson | F | 66 | 6 years | |
Michael Powell | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
Alexandra Kropotova | M | 51 | 5 years | |
Philip Needleman | M | - |
G.D. Searle LLC
| 4 years |
Paul Fitzhenry | M | 64 | 4 years | |
Deborah Dunsire | M | 61 | 9 years | |
William Herbert Gray | M | 82 | 13 years | |
Matthew Onaitis | M | 53 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | - |
Robert N. Burt | M | 86 | 11 years | |
Michael R. Jirousek | M | 65 | 5 years | |
Peter Corr | M | 76 | 6 years | |
Tod Smeal | M | 59 | 12 years | |
Charles Baum | M | 65 | 9 years | |
Gail Cawkwell | M | 62 | 14 years | |
Anna Levander | F | 47 | 3 years | |
James Christensen | M | 55 | 10 years | |
Dario Paggiarino | M | 67 | 10 years | |
Catherine Knupp | M | 63 | - | |
Mariano García-Valiño | M | 58 | 8 years | |
Mary Winston | F | 62 | 7 years | |
Arthur Lee Campbell | M | 73 | - | |
Joseph Monahan | M | 69 | 7 years | |
David J. Wustrow | M | 65 | 2 years | |
Rajiv Sarman Shukla | M | 49 | 5 years | |
Rajmund Ireneusz Martyniuk | M | 62 | 4 years | |
Carol Szeto | F | - | 6 years | |
Julie Krop | M | 57 | 2 years | |
William Pringle | M | 56 | 6 years | |
Michael Bruce | M | - | 12 years | |
Michael Warner | M | - | 16 years | |
Tanya de Foras | F | 53 | 10 years | |
Adrian Otte | M | - | 6 years | |
Muriel Cottard | M | - | 4 years | |
Mark J. Taisey | M | - | 5 years | |
Deborah Baron | F | 55 | - | |
Edmund Harrigan | M | 71 | 12 years | |
Bruce Curtis Crosby | M | - | 2 years | |
Michelle Nasir | F | - | 6 years | |
Jeffrey Kent | M | 62 | 4 years | |
Matthew Rossen | M | 47 | 9 years | |
John Chapman | M | 70 | 4 years | |
Feng Guo | M | 54 | 11 years | |
Viviane Monges | F | 60 | 5 years | |
Mark White | M | 68 | 12 years | |
John F. Niblack | M | 85 | 35 years | |
Alexander Polinsky | M | 67 | 8 years | |
Krishan K. Arora | M | 83 | 5 years | |
William J. Creelman | M | 69 | 1 years | |
William J. Robison | M | 88 | 40 years | |
Philip D. Worboys | M | 54 | 2 years | |
Brian Goldberg | M | 50 | 2 years | |
Linda Armstrong | M | 61 | 6 years | |
William Sigmund | M | - | 4 years | |
Kenneth Bahrt | M | 71 | 4 years | |
Marc Robinson | M | 63 | 6 years | |
Warren R. Winter | M | - | 15 years | |
Claus Egstrand | M | 63 | 3 years | |
Scott Kay | M | - | 7 years | |
Pat Parr | M | - | 6 years | |
Robert Zerbe | M | 73 | 7 years | |
Michael Berendt | M | 75 | 18 years | |
Wendell Wierenga | M | 76 | 10 years | |
Christopher S. Hassan | M | 63 | 4 years | |
Steven Ward | M | 64 | 15 years | |
William R. Howell | M | 88 | 9 years | |
Malvina Laudicina | F | 65 | 5 years | |
Ebrahim Versi | M | 71 | 4 years | |
Thomas G. Gant | M | - | 6 years | |
Nicholas Lee Gurreri | M | - | 4 years | |
Annika Berg | F | 61 | 2 years | |
Charles McWherter | M | 69 | 4 years | |
Beth Anne Piper | M | - | 3 years | |
Marylou Walker | F | 58 | 10 years | |
Frank Sciavolino | M | 83 | 35 years | |
William J. Slichenmyer | M | 66 | 7 years | |
Yvonne R. Jackson | F | 74 | 3 years | |
Julie A. Olson | M | - | 19 years | |
James L. Freddo | M | 69 | 3 years | |
Navin Jacob | M | - | 3 years | |
Allen Waxman | M | 61 | 5 years | |
Jing Wei Zhang | M | 56 | 20 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Karen Potts
- Personal Network